Cargando…

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

SIMPLE SUMMARY: A subset of patients with pancreatic cancer demonstrate heightened response rates and prolonged survival to platinum chemotherapy and PARP inhibitors. Deficient homologous recombination (HR), a critical DNA repair program, is a major driver of this susceptibility. Furthermore, the cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wattenberg, Max M., Reiss, Kim A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466888/ https://www.ncbi.nlm.nih.gov/pubmed/34572943 http://dx.doi.org/10.3390/cancers13184716

Ejemplares similares

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
por: Casolino, Raffaella, et al.
Publicado: (2021)

Genomic Determinants of Homologous Recombination Deficiency across Human Cancers
por: Qing, Tao, et al.
Publicado: (2021)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review
por: Tan, Heng, et al.
Publicado: (2023)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level
por: Zhuang, Shuping, et al.
Publicado: (2021)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies
por: Pokataev, Ilya, et al.
Publicado: (2020)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort
por: Rădoi, Viorica-Elena, et al.
Publicado: (2023)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
por: da Cunha Colombo Bonadio, Renata Rodrigues, et al.
Publicado: (2018)

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
por: Pacheco-Barcia, Vilma, et al.
Publicado: (2022)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
por: Pellegrino, B., et al.
Publicado: (2020)

Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Multi-scale characterisation of homologous recombination deficiency in breast cancer
por: Jacobson, Daniel H., et al.
Publicado: (2023)

Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
por: Ladan, Marjolijn M., et al.
Publicado: (2021)

Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer
por: Kim, Seung Jin, et al.
Publicado: (2020)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
por: Wattenberg, Max M., et al.
Publicado: (2021)

Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers
por: Hsiao, Yi-Wen, et al.
Publicado: (2021)

Prediction of homologous recombination deficiency from cancer gene expression data
por: Kang, Jun, et al.
Publicado: (2022)

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
por: Ngoi, N.Y.L., et al.
Publicado: (2021)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
por: Quesada, Stanislas, et al.
Publicado: (2022)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
por: Quesada, Stanislas, et al.
Publicado: (2022)

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer
por: Khaddour, Karam, et al.
Publicado: (2022)

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
por: Tsantikidi, Aikaterini, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p66941ehnk7dikds1048huj0uf